The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Keryx Biopharmaceuticals to Present at The Oppenheimer & Co. Inc. 23rd Annual Healthcare Conference

Monday, December 10, 2012

Keryx Biopharmaceuticals to Present at The Oppenheimer & Co. Inc. 23rd Annual Healthcare Conference08:30 EST Monday, December 10, 2012Presentation Scheduled for Thursday, December 13th at 3:55pm ETNEW YORK, Dec. 10, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the Oppenheimer & Co. Inc. 23rd Annual Healthcare Conference, being held December 12-13, 2012, in New York City. Mr. Bentsur's presentation is scheduled to take place on Thursday, December 13, 2012 at 3:55pm Eastern Time. A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.About Keryx Biopharmaceuticals, Inc.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Zerenex is also in Phase 2 development for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.  Keryx is headquartered in New York City. KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail: lfischer@keryx.comSOURCE Keryx Biopharmaceuticals, Inc.